Advances in Device and Formulation Technologies for Pulmonary Drug Delivery

Chan, John Gar Yan; Wong, John; Zhou, Qi Tony; Leung, Sharon Shui Yee; Chan, Hak‐Kim

doi:10.1208/s12249-014-0114-y

Cited by 65 publications

(31 citation statements)

References 182 publications

(214 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dry powder inhaler (DPI) drugs (114)(115)(116)(117), drug-eluting stents (118,119), and insulin pumps (120,121) are examples of widely used drug-device combinations, with many reports on their benefits and limitations. Although most drugs used in drug-device combinations are small molecules, significant progress has been made for delivering peptides and proteins, while maintaining their stability and activity.…”

Section: Drug-device Combinationsmentioning

confidence: 99%

Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges

Wen¹,

Jung²,

2015

AAPS J

443

189

View full text Add to dashboard Cite

Abstract. Various drug delivery approaches can be used to maximize therapeutic efficacy and minimize side effects, by impacting absorption, distribution, metabolism, and elimination (ADME) of a drug compound. For those drugs with poor water solubility or low permeability, techniques such as amorphous solid dispersion, liposomes, and complexations have been used to improve their oral bioavailability. Modified release (MR) formulations have been widely used to improve patient compliance, as well as to reduce side effects, especially for those drugs with short half-lives or narrow therapeutic windows. More than ten drugs using sterile long-acting release (LAR) formulations with clear clinical benefit have been successfully marketed. Furthermore, drug delivery systems have been used in delaying drug clearance processes. Additionally, modifying the in vivo drug distribution using targeted delivery systems has significantly improved oncology treatments. All the drug delivery approaches have their advantages and limitations. For both brand and generic drugs, the achievement of consistent quality and therapeutic performance using drug delivery systems can also pose serious challenges in developing a drug for the market, which requires close collaboration among industry, academia, and regulatory agencies. With the advent of personalized medicines, there will be great opportunities and challenges in utilizing drug delivery systems to provide better products and services for patients.

show abstract

Section: Drug-device Combinationsmentioning

confidence: 99%

Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges

Wen¹,

Jung²,

2015

AAPS J

443

189

View full text Add to dashboard Cite

show abstract

“…The vibrating mesh nebulizer overcomes some of the disadvantages observed with the first two nebulizer types, like lowering the total treatment time, minimal residual drug volumes, and better efficiency in drug delivery to the lung. However, the complicated operational procedures for nebulizers along with their high cost remains a barrier to better patience compliance (Ari and Fink, 2013;Chan et al, 2014;Ibrahim, Verma and Garcia-Contreras, 2015;Tashkin, 2016).…”

Section: Problems Associated With Different Inhaler Devicesmentioning

confidence: 99%

“…Active inhaler devices disperse powders based on an external energy source such as compressed air, electrical vibration, and mechanical barriers. Although a few active dry powder inhalers have been clinically tested (Hoppentocht et al, 2014a), their widespread use in the future may be hindered due to their complexity, expense, failure due to the requirement for an external energy source, and most importantly, poor patient compliance due to the numerous operational steps required for inhalation (Smutney, Grant and Kinsey, 2013;Chan et al, 2014;de Boer et al, 2017).…”

Section: Device Innovationmentioning

confidence: 99%

Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing

Price

Kunda

Muttil

2019

KONA

View full text Add to dashboard Cite

Significant progress has been made over the last half-century in delivering therapeutics by the pulmonary route. Inhaled therapeutics are administered to humans using metered-dose inhalers, nebulizers, or dry powder inhalers, and each device requires a different formulation strategy for the therapeutic to be successfully delivered into the lung. In recent years, there has been a shift to the use of dry powder inhalers due to advantages in the consistency of the dose delivered, ease of administration, and formulation stability. Numerous preclinical studies, involving small and large animals, have evaluated dry powder drugs, vaccines, and immunotherapeutics delivered by the pulmonary route. These studies used different dry powder delivery devices including nose-only, whole-body, and intratracheal administration systems, each of which works with different aerosolization mechanisms. Unfortunately, these delivery platforms usually lead to variable powder deposition in the respiratory tract of animals. In this review, we will discuss obstacles and variables that affect successful pulmonary delivery and uniform powder deposition in the respiratory tract, such as the type of delivery device, dry powder formulation, and the animal model used. We will conclude by outlining factors that enhance the reproducible deposition of dry powders in the respiratory tract of preclinical animal models and identifying knowledge and technology gaps within the field. We will also outline the important factors necessary for successful translation of studies performed in preclinical models to humans.

show abstract

“…Another critical factor affecting the reproducibility of doses delivered by multidose inhalers is dose metering. While single-dose and multi-unit dose devices use premetered powders packed into blisters or capsules, powder bed bulk multidose inhalers use powder reservoirs so that the dose to be delivered has to be separated from the bulk material prior to actuation (34). For both types of devices, suitable powder flow properties are essential, either for accurate dosing or emptying of the single-dose container entirely.…”

Section: General Requirements For Dry Powder Inhalation Devicesmentioning

confidence: 99%

Devices for Dry Powder Drug Delivery to the Lung

2015

View full text Add to dashboard Cite

Abstract. Dry powder inhalers (DPIs) are an important and increasingly investigated method of modern therapy for a growing number of respiratory diseases. DPIs are a promising option for certain patient populations, and may help to overcome several limitations that are associated with other types of inhalation delivery systems (e.g., accuracy and reproducibility of the dose delivered, compliance and adherence issues, or environmental aspects). Today, more than 20 different dry powder inhalers are on the market to deliver active pharmaceutical ingredients (APIs) for local and/or systemic therapy. Depending on the mechanism of deagglomeration, aerosolization, dose metering accuracy, and the interpatient variability, dry powder inhalers demonstrate varying performance levels. During development, manufacturers focus on improving aspects characteristic of their specific DPI devices, depending on the intended type of application and any particular requirements associated with it. With the wide variety of applications related to specific APIs, there exists a range of different devices with distinct features. In addition to the routinely used multi-use DPIs, several single-use disposable devices are under development or already approved. The recent introduction of disposable devices will expand the range of possible applications for use by including agents such as vaccines, analgesics, or even rescue medications. This review article discusses the performance and advantages of recently approved dry powder inhalers as well as disposable single-use inhalers that are currently under development.

show abstract

Advances in Device and Formulation Technologies for Pulmonary Drug Delivery

Cited by 65 publications

References 182 publications

Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges

Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges

Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing

Devices for Dry Powder Drug Delivery to the Lung

Contact Info

Product

Resources

About